相似文献
1
Trends in primary androgen depletion therapy for patients with localized and locally advanced prostate cancer: Japanese perspective.
Cancer Sci. 2006 Apr;97(4):243-7. doi: 10.1111/j.1349-7006.2006.00180.x.
2
Hormonal therapy.
Int J Clin Oncol. 2007 Dec;12(6):427-32. doi: 10.1007/s10147-007-0704-8. Epub 2007 Dec 21.
3
Patterns of Declining Use and the Adverse Effect of Primary Androgen Deprivation on All-cause Mortality in Elderly Men with Prostate Cancer.
Eur Urol. 2015 Jul;68(1):32-9. doi: 10.1016/j.eururo.2014.10.018. Epub 2014 Oct 29.
4
Age at diagnosis on prostate cancer survival undergoing androgen deprivation therapy as primary treatment in daily practice: results from Japanese observational cohort.
J Cancer Res Clin Oncol. 2014 Jul;140(7):1197-204. doi: 10.1007/s00432-014-1638-y. Epub 2014 Mar 28.
5
National practice patterns and time trends in androgen ablation for localized prostate cancer.
J Natl Cancer Inst. 2003 Jul 2;95(13):981-9. doi: 10.1093/jnci/95.13.981.
6
Primary Androgen-Depletion Therapy Prevails Not Only for Metastatic but Also for Nonmetastatic Hormone-Naïve Prostate Cancer in Japan-Recent Trends and Efficacy.
Gan To Kagaku Ryoho. 2021 Jul;48(7):911-919.
7
Clinical outcomes and nadir prostate-specific antigen (PSA) according to initial PSA levels in primary androgen deprivation therapy for metastatic prostate cancer.
World J Urol. 2016 Mar;34(3):319-27. doi: 10.1007/s00345-015-1621-5. Epub 2015 Jun 19.
8
The case for androgen deprivation as primary therapy for early stage disease: results from J-CaP and CaPSURE.
J Urol. 2006 Dec;176(6 Pt 2):S47-9. doi: 10.1016/j.juro.2006.06.070.
9
Survival following primary androgen deprivation therapy among men with localized prostate cancer.
JAMA. 2008 Jul 9;300(2):173-81. doi: 10.1001/jama.300.2.173.
10
Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Cancer. 2006 Apr 15;106(8):1708-14. doi: 10.1002/cncr.21799.
引用本文的文献
1
Primary management of prostate cancer by universal health coverage effective coverage index.
World J Urol. 2025 Mar 4;43(1):146. doi: 10.1007/s00345-025-05530-7.
2
Long-term outcomes of androgen deprivation therapy in prostate cancer among Japanese men over 80 years old.
Cancer Sci. 2021 Aug;112(8):3074-3082. doi: 10.1111/cas.14974. Epub 2021 Jun 29.
3
The change of prostate cancer treatment in Korea: 5 year analysis of a single institution.
Yonsei Med J. 2013 Jan 1;54(1):87-91. doi: 10.3349/ymj.2013.54.1.87.
4
Genetic polymorphisms of CYP17A1 in steroidogenesis pathway are associated with risk of progression to castration-resistant prostate cancer in Japanese men receiving androgen deprivation therapy.
Int J Clin Oncol. 2013 Aug;18(4):711-7. doi: 10.1007/s10147-012-0430-8. Epub 2012 Jun 21.
5
Blockade of testicular and adrenal androgens in prostate cancer treatment.
Nat Rev Urol. 2011 Feb;8(2):73-85. doi: 10.1038/nrurol.2010.231. Epub 2011 Jan 18.
6
Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks.
Eur Urol. 2009 Jan;55(1):62-75. doi: 10.1016/j.eururo.2008.10.008. Epub 2008 Oct 14.
7
Leuprorelin depot injection: patient considerations in the management of prostatic cancer.
Ther Clin Risk Manag. 2008 Apr;4(2):513-26. doi: 10.2147/tcrm.s6863.
8
Survival following primary androgen deprivation therapy among men with localized prostate cancer.
JAMA. 2008 Jul 9;300(2):173-81. doi: 10.1001/jama.300.2.173.
本文引用的文献
1
Clinical characteristics of prostate cancer in Japanese men in the eras before and after serum prostate-specific antigen testing.
Int J Urol. 2005 Jul;12(7):662-7. doi: 10.1111/j.1442-2042.2005.01113.x.
2
Androgen deprivation therapy for prostate cancer.
JAMA. 2005 Jul 13;294(2):238-44. doi: 10.1001/jama.294.2.238.
3
20-year outcomes following conservative management of clinically localized prostate cancer.
JAMA. 2005 May 4;293(17):2095-101. doi: 10.1001/jama.293.17.2095.
4
Major impact of hormonal therapy in localized prostate cancer--death can already be an exception.
J Steroid Biochem Mol Biol. 2004 Dec;92(5):327-44. doi: 10.1016/j.jsbmb.2004.10.011. Epub 2004 Dec 21.
5
Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer.
J Clin Oncol. 2005 Feb 1;23(4):808-15. doi: 10.1200/JCO.2005.12.013.
6
Clinicopathological statistics on registered prostate cancer patients in Japan: 2000 report from the Japanese Urological Association.
Int J Urol. 2005 Jan;12(1):46-61. doi: 10.1111/j.1442-2042.2004.00984.x.
7
Timeline: Chemotherapy and the war on cancer.
Nat Rev Cancer. 2005 Jan;5(1):65-72. doi: 10.1038/nrc1529.
8
Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years.
J Urol. 2004 Nov;172(5 Pt 1):1865-70. doi: 10.1097/01.ju.0000140159.94703.80.
9
Characteristics of patients with prostate cancer who have initially been treated by hormone therapy in Japan: J-CaP surveillance.
Jpn J Clin Oncol. 2004 Jun;34(6):329-36. doi: 10.1093/jjco/hyh061.
10
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
JAMA. 2004 Aug 18;292(7):821-7. doi: 10.1001/jama.292.7.821.
Zotero 插件